Anti-CD166 / ALCAM Magnetic Beads-IP Kit Product Components
| Components | Storage |
| Anti-CD166 / ALCAM Magnetic Beads1,3 | 2-8℃ for 12 months |
| NP40 Cell Lysis Buffer2 | -20℃ for 12 months |
| 5×TBST（pH7.4） | |
| 1×TBST（pH7.4） | |
| ddH2O | |
| CD166 Positive Cell Lysate | -20℃ for 12 months |
| Alkaline Elution Buffer | 2-8℃ for 12 months |
| Acidity Elution Buffer | 2-8℃ for 12 months |
| Neutralization Buffer | 2-8℃ for 12 months |
[1] The IP KIT contains anti-CD166 / ALCAM magnetic Beads (2 mg/mL) in phosphate buffered saline (PBS, pH 7.4) with sodium azide (0.1%).
[2] Using NP-40 cell lysate buffer in the kit is required,otherwise,the magnetic beads may be precipitated.
[3] Shipping: Magnetic Beads kits are shipped at ambient temperature in which magnetic beads are provided in liquid buffer.
Anti-CD166 / ALCAM Magnetic Beads-IP Kit Product Description
The Anti-CD166 / ALCAM magnetic Beads, conjugated with Anti-CD166 / ALCAM antibody, are used for immuneprecipitation (IP) of CD166 / ALCAM proteins which expressed in vitro expression systems. For IP, the beads are added to a sample containing CD166 / ALCAM proteins to form a bead-protein complex. The complex is removed from the solution manually using a magnetic separator. The bound CD166 / ALCAM proteins are dissociated from the magnetic beads using an elution buffer. Anti-CD166 / ALCAM Magnetic Beads-IP Kit Antibody Information
Immunogen
Recombinant Cynomolgus CD166 / ALCAM protein (Catalog#90227-C08H)
Species Reactivity
Cynomolgus CD166 / ALCAM
Source
Polyclonal Cynomolgus Rabbit IgG
Preparation
Produced in rabbits immunized with purified, recombinant Cynomolgus CD166 / ALCAM (rh CD166 / ALCAM; Catalog#90227-C08H; G7NZQ8; Met1-Ala526). CD166 / ALCAM specific IgG was purified by Cynomolgus CD166 / ALCAM affinity chromatography.
Applications
Immunoprecipitation (IP), Minimum Protein Purification
CD166 / ALCAM Background Information
Activated leukocyte cell adhesion molecule (ALCAM)/Cluster of differentiation (CD166) is a type I transmembrane cell adhesion molecule belonging to the Ig superfamily and a ligand for CD6 that is expressed on T lymphocytes. The extracellular domain of ALCAM contains five Ig-like domains (three Ig-like C2-type domains and two Ig-like V-type domains), of which the amino-terminal V1 domain is essential for ligand binding and ALCAM-mediated cell aggregation. ALCAM mediates both heterophilic (ALCAM-CD6) and homophilic (ALCAM-ALCAM) cell-cell interactions. ALCAM/CD6 interaction plays a role in T cell development and T cell regulation, as well as in the binding of T- and B-cells to activated leukocytes. Recently, homophilic (ALCAM-ALCAM) adhesion was shown to play important roles in tight cell-to-cell interaction and regulation of stem cell differentiation. While expressed in a wide variety of tissues, ALCAM is usually restricted to subsets of cells involved in dynamic growth and/or migration, including neural development, branching organ development, hematopoiesis, immune response and tumor progression. And CD166 is regarded as a potential novel breast cancer indicator and therapeutic target.
Full Name
activated leukocyte cell adhesion molecule
References
Swart GW. (2002) Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol. 81(6): 313-21. Fujiwara H, et al. (2003) Human blastocysts and endometrial epithelial cells express activated leukocyte cell adhesion molecule (ALCAM/CD166). J Clin Endocrinol Metab. 88(7): 3437-43. Jezierska A, et al. (2006) ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit. 12(8): BR263-73. Kahlert C, et al. (2009) Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer. 101(3): 457-64.
新浪微博
腾讯微博
QQ空间
客服
